Press Releases for MDVN

Press Releases
Medivation Reports Second Quarter 2009 Financial Results and Provides Corporate Update
Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
Medivation Announces Second Quarter 2009 Financial Results Teleconference and Webcast on August 5, 2009
Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease
Medivation to Present at 8th Annual Needham Life Sciences Conference
Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
Medivation Announces Pricing of Public Offering
Medivation Selects ProTrials to Conduct International Phase III Clinical Trials
Medivation Announces Offering of 2,750,000 Shares of Common Stock
Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting
Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
Medivation Reports First Quarter 2009 Financial Results and Provides Corporate Update
Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
Medivation Announces Upcoming Scientific Presentations at Medical Conferences
Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease
Medivation Announces Publication in Science Describing MDV3100's Novel and Potent Anti-Androgen Properties
Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
Medivation Announces Participation in Upcoming Conferences
Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
Medivation Presents New Data on Dimebon's Novel Mechanism of Action
Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
Medivation Announces Upcoming Data Presentations on Dimebon's Mechanism of Action
Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
Medivation Announces Participation in Upcoming Investor Conferences
Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
Medivation Receives Corporate Achievement Award From Huntington's Disease Society of America
Pfizer and Medivation Enter into Global Agreement to Co-Develop and Market Dimebon for the Treatment of Alzheimer's and Huntington's Diseases
Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
Medivation Announces Participation in Upcoming Conferences - Sep 9 2008 2:29AM
Alzheimer's Disease and Emerging Treatments Analyzed in Neurotech Insights
Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
/C O R R E C T I O N -- Medivation, Inc./
Medivation Presents Positive New Data on Dimebon's Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimer's Disease
Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease
Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntington's Disease
Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntington's Disease
Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimer's Disease
Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting - May 27 2008 12:55AM
Medivation Reports First Quarter 2008 Financial Results and Provides Corporate Update - Jun 2 2008 12:54AM
Medivation Announces Participation in Upcoming Conferences - Jun 2 2008 12:54AM
Medivation Announces First Quarter 2008 Teleconference and Webcast on May 1, 2008
Medivation's Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimer's Disease Patients Over One Year
Medivation's Dimebon(TM) Significantly Improved Daily Function in Alzheimer's Disease Patients, Resulting in Reduced Need for Caregiver Assistance
Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients